Mylan Shares Still Not Getting Enough Respect; UBS Likes News Of Expansion Into Tropicals

UBS' Matt Miksic expressed his enthusiasm for Mylan Inc. MYL after the company announced its plans to acquire Renaissance's Tropical/Generics for $950 in cash.

"The manufacturing facilities and dermatologist sales force (we estimate 50-100 reps) add an important capability that helps further strengthen Mylan's position in the topical/dermatology market" the UBS analyst stated. This deal fit well into the overall Mylan strategy and expanded the company into a more profitable environment with less competitors said Miksic.

The analyst noted investors may remain upset due to the fact that much of the earnings growth is "deal related." Miksic said not to worry though, as Mylan's management team "has consistently put up strong double digit earnings growth for many years and the forecast for the next few years remains the same."

UBS kept its $66 12-month price objective as a result of continued future catalysts.